T. Wiegel

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Th Wiegel, T. Wiegel, Thomas Wiegel, Th. Wiegel, T Wiegel
Publication record
426 papers · 26,843 citations · H-index 54

PAPERS

ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer
202323 citationsauthor #12
Effect of undetectable PSA following SRT for biochemical recurrence on BPFS, FFM, and OS.
20230 citationsauthor #7
ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer.
202326 citationsauthor #13
Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer.
202317 citationsauthor #11
Multi-institutional Development and External Validation of a Machine Learning Model for the Prediction of Distant Metastasis in Patients Treated by Salvage Radiotherapy for Biochemical Failure After Radical Prostatectomy.
20233 citationsauthor #6
EPIC-26 urinary incontinence score results and pad use 12 months after radical prostatectomy for localized or (locally) advanced prostate cancer: Results of a cohort of 14,920 patients from 118 certified centers in Germany, Switzerland, and Austria.
20230 citationsauthor #10
Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer
202329 citationsauthor #27
Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study.
202319 citationsauthor #36
OC-0435 Multi-institutional nomogram for PSMA-PET based salvage radiotherapy in recurrent prostate cancer
20230 citationsauthor #20
Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review.
202325 citationsauthor #31
HIGH RATE OF METABOLIC COMPLETE RESPONSE AFTER LOW DOSE RADIOTHERAPY AND OBINUTUZUMAB IN EARLY STAGE FOLLICULAR LYMPHOMA: INITIAL RESULTS OF THE GAZAI STUDY (GLA 2018‐3)
20230 citationsauthor #15
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study.
202330 citationsauthor #17
Development and validation of a multi-institutional nomogram of outcomes for PSMA-PET–based salvage radiotherapy in recurrent prostate cancer.
20230 citationsauthor #17
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
202317 citationsauthor #22
Head-to-head comparison of mpMRI and PET imaging using [F-18]siPSMA-14 in primary staging of prostate cancer patients
20230 citationsauthor #4
SP-0998 ESTRO-ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer
20230 citationsauthor #12
PD-0569 Quality of life results from the Prostate Cancer Outcome Study (PCO) after primary radiotherapy
20230 citationsauthor #11
Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre
20237 citationsauthor #7
MP48-09 TOXICITY PROFILE OF IMMEDIATE POST-PROSTATECTOMY RADIATION THERAPY: RESULTS FROM A LARGE MULTI-INSTITUTIONAL SERIES
20220 citationsauthor #20
Metastasis-free survival and patterns of distant metastatic disease after PSMA-PET-guided salvage radiotherapy in recurrent or persistent prostate cancer after prostatectomy.
202228 citationsauthor #31
Impact of Dose Escalation on the Efficacy of Salvage Radiotherapy for Recurrent Prostate Cancer—A Risk-Adjusted, Matched-Pair Analysis
20226 citationsauthor #5
PSA doubling time as predictor of relapse after early salvage radiation therapy: When should imaging be used to select patients who might not benefit from early local treatments?
20220 citationsauthor #20
PSMA-PET und „radio-guided surgery“ bei zervikaler Lymphadenektomie
20221 citationsauthor #3
Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases
20225 citationsauthor #17
Challenges and Solutions during the COVID Pandemic for Patient Retention and Physician Engagement in the Phase 3 ATLAS Study of Apalutamide Added to Androgen Deprivation Therapy (ADT) in High-Risk Localized or Locally Advanced Prostate Cancer (HRLPC)
20220 citationsauthor #12
Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients
20227 citationsauthor #17
Postoperative Radiotherapy of Prostate Cancer: Adjuvant versus Early Salvage
20221 citationsauthor #9
A nested case-control study on radiation dose-response for cardiac events in breast cancer patients in Germany
20228 citationsauthor #14
Genomic classifiers in personalized prostate cancer radiotherapy approaches - a systematic review and future perspectives based on international consensus.
202220 citationsauthor #30
Short-Interval, Low-Dose Peptide Receptor Radionuclide Therapy in Combination with PD-1 Checkpoint Immunotherapy Induces Remission in Immunocompromised Patients with Metastatic Merkel Cell Carcinoma
202214 citationsauthor #7
Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients
20220 citationsauthor #17
LBA75 RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results
20227 citationsauthor #12
The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy.
20222 citationsauthor #5
PO-1414 Results of a concept-development for a phase III trial on radiotherapy in primary prostate cancer
20220 citationsauthor #16
671P Postoperative chemoradiation in combination with cetuximab followed by 6-months cetuximab maintenance in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence
20220 citationsauthor #12
Machine Learning for the Prediction of Lymph Node Metastasis in Patients with Prostate Cancer
20220 citationsauthor #10
Machine Learning for the Prediction of Distant Metastases Following Postprostatectomy Salvage Radiation Therapy
20220 citationsauthor #9
Radiotherapy in nodal oligorecurrent prostate cancer
202112 citationsauthor #15
PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
202140 citationsauthor #13
Options for Curative Treatment of Localized Prostate Cancer.
202122 citationsauthor #6
Timing of ADT in Radiotherapy of Prostate Cancer.
20210 citationsauthor #3
Re: Timing of Radiotherapy After Radical Prostatectomy (RadicalS-RT): A Randomised, Controlled Phase 3 Trial.
20212 citationsauthor #2
Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.
202181 citationsauthor #34
Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature.
202147 citationsauthor #3
Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review.
202124 citationsauthor #19
There is no way to compensate a non-timely use of early salvage radiation therapy in men with recurrent Prostate Cancer after Radical Prostatectomy. A retrospective, multi-centre analyses on oncological and toxicity outcomes
20210 citationsauthor #22
The key role of PSA doubling time in patients treated with salvage radiation therapy after radical prostatectomy: Implications for the extent of radiation and the concomitant use of hormonal therapy
20210 citationsauthor #21
Assessing the effect of concomitant hormonal therapy on severe toxicity in patients treated with post-prostatectomy radiation therapy: Results from a large, multi-institutional study
20210 citationsauthor #24
Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa)
202113 citationsauthor #9
Postoperative radiotherapy in prostate cancer.
20211 citationsauthor #3
Very long-term outcomes, time patterns of recurrence and other-cause mortality in patients treated with salvage radiation therapy for recurrent prostate cancer after radical prostatectomy: Implications for risk tailored follow-up strategies
20210 citationsauthor #22
Die Therapie des primär oligometastasierten Prostatakarzinoms
20212 citationsauthor #3
Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
202150 citationsauthor #25
Reply to Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, Joerg Zimmermann and Stefan Machten’s to the Letter to the editor Re: results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)
20210 citationsauthor #1
Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries
20215 citationsauthor #17
Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations
202118 citationsauthor #43
PD08-03 EAU BCR RISK CLASSIFICATION AS DECISION TOOL FOR SALVAGE RADIOTHERAPY? A MULTICENTER STUDY
20210 citationsauthor #17
OC-0508 ESTRO ACROP Guideline on Prostate Bed Delineation for Postoperative Radiotherapy in Prostate Cancer
20210 citationsauthor #12
EAU BCR risk classification as decision tool for salvage radiotherapy? A multicenter study
20210 citationsauthor #17
A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer.
202138 citationsauthor #24
A Multi-Institutional Analysis of Prostate Cancer Patients With or Without 68Ga-PSMA PET/CT Prior to Salvage Radiotherapy of the Prostatic Fossa
20217 citationsauthor #17
A systematic review on the impact of surgeon and hospital caseload volume on oncological and non-oncological outcomes after radical prostatectomy for non-metastatic prostate cancer
20210 citationsauthor #23
What is the optimal duration of hormonal treatment during salvage radiotherapy in men with pN1 Prostate Cancer? Results form a large Multi-Institutional series
20210 citationsauthor #23
Comparison of salvage radiation therapy delivered for PSA persistence versus PSA relapse after radical prostatectomy: How is the outcome changing?
20210 citationsauthor #24
Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death
202194 citationsauthor #6
Correction to: Value of PET imaging for radiation therapy
20211 citationsauthor #32
Correction to: Value of PET imaging for radiation therapy
20211 citationsauthor #71
Changes of Radiation Treatment Concept Based on 68Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy
202111 citationsauthor #10
Ultrahypofractionation of localized prostate cancer
202024 citationsauthor #17
Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis
20209 citationsauthor #10
Current treatment options for locally advanced prostate cancer: EAU (-SIOG) guidelines view and recommendations
20200 citationsauthor #25
Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma
202010 citationsauthor #5
MP37-17 CHANGING PATTERNS AND PREDICTORS OF SALVAGE RADIATION THERAPY USE OVER TIME IN PATIENTS TREATED FOR POST-PROSTATECTOMY BIOCHEMICAL RECURRENCE: A TREND ANALYSIS OVER A 20-YEAR PERIOD FROM A MULTI-INSTITUTIONAL SERIES
20200 citationsauthor #24
Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer
202014 citationsauthor #14
Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer.
20200 citationsauthor #5
Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer.
20207 citationsauthor #6
PD-0671: Matched pair analysis of salvage radiotherapy vs observation for post-prostatectomy PSA recurrence
20200 citationsauthor #1
Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: a stage-specific analysis from a large multi-institutional series
20200 citationsauthor #25
Androgen deprivation therapy plus salvage radiotherapy after prostatectomy.
20201 citationsauthor #2
First Experiences with 177Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients
202016 citationsauthor #6
Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
2020128 citationsauthor #32
Cure without toxicity: development of a novel model predicting trifecta outcomes after salvage radiation therapy for recurrent prostate cancer after radical prostatectomy
20200 citationsauthor #24
Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations.
2020202 citationsauthor #20
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250].
20207 citationsauthor #117
Association between the extent of lymph node dissection and severe toxicity in men with prostate cancer treated with post-prostatectomy radiation therapy: results from a large multi-institutional series
20200 citationsauthor #24
Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy
202040 citationsauthor #9
The EAU biochemical recurrence risk stratification after radical prostatectomy
20201 citationsauthor #20
Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)
202011 citationsauthor #1
Correction to: Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)
20200 citationsauthor #1
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
2020892 citationsauthor #25
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
20202,557 citationsauthor #25
Changing patterns and predictors of salvage radiation therapy use over time in patients treated for post-prostatectomy biochemical recurrence: a trend analysis over a 20-year period from a multi institutional series
20200 citationsauthor #24
Moving Beyond the Hazard Ratio to Personalized Therapy: Is it Prime Time?
20200 citationsauthor #3
MP37-16 ASSESSING THE IMPACT OF SALVAGE RADIATION THERAPY FIELD AFTER RADICAL PROSTATECTOMY: A LONG-TERM ANALYSIS FROM A LARGE MULTI-INSTITUTIONAL SERIES
20200 citationsauthor #24
Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial
20204 citationsauthor #2
MP37-11 ASSOCIATION BETWEEN THE EXTENT OF LYMPH NODE DISSECTION AND SEVERE TOXICITY IN MEN WITH PROSTATE CANCER TREATED WITH POST-PROSTATECTOMY RADIATION THERAPY: RESULTS FROM A LARGE MULTI-INSTITUTIONAL SERIES
20200 citationsauthor #24
LBA58 ORR in patients receiving nivolumab plus radiotherapy in advanced non-small cell lung cancer: First results from the FORCE trial
20208 citationsauthor #11
MP53-02 SALVAGE RADIOTHERAPY VERSUS OBSERVATION FOR BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY FOR PROSTATE CANCER: A MATCHED PAIR ANALYSIS
20200 citationsauthor #2
Re: Gaëtan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.04.016.
20190 citationsauthor #3
The impact of prostate‐specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer
201921 citationsauthor #5

TIMELINE

1988 0 citations

1989 7 citations

1991 12 citations

1992 34 citations

1993 14 citations

1994 22 citations

1995 63 citations

1996 10 citations

1997 120 citations

1998 217 citations

1999 39 citations

2000 65 citations

2001 57 citations

2002 402 citations

2003 6 citations

2004 150 citations

2005 267 citations

2006 86 citations

2007 317 citations

2008 8 citations

2009 1,007 citations

2010 844 citations

2011 3,604 citations

2012 619 citations

2013 1,401 citations

2014 4,425 citations

2015 265 citations

2016 378 citations

2017 5,758 citations

2018 609 citations

2019 1,028 citations

2020 3,931 citations

2021 468 citations

2022 99 citations

2023 196 citations

Unknown 177 citations

T. Wiegel

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT